Clover hea_老虎社区_美港股上老虎

2021-12-26

Clover health did not pay investorplace to write this report.

Clover Health Is Not the $2 Billion Stock to Buy for 2022

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698411090,"tweetId":"698411090","gmtCreate":1640490269829,"gmtModify":1640490270833,"author":{"id":3577178099298017,"idStr":"3577178099298017","authorId":3577178099298017,"authorIdStr":"3577178099298017","name":"DragonKC","avatar":"https://static.tigerbbs.com/f90c63c67a4e5f91e9dc0159f5b853ab","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":97,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Clover health did not pay investorplace to write this report.&nbsp;</body></html>","htmlText":"<html><head></head><body>Clover health did not pay investorplace to write this report.&nbsp;</body></html>","text":"Clover health did not pay investorplace to write this report.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698411090","repostId":1166698166,"repostType":4,"repost":{"id":"1166698166","kind":"news","pubTimestamp":1640484465,"share":"https://www.laohu8.com/m/news/1166698166?lang=&edition=full","pubTime":"2021-12-26 10:07","market":"us","language":"en","title":"Clover Health Is Not the $2 Billion Stock to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1166698166","media":"InvestorPlace","summary":"Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth ","content":"Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the special purpose acquisition company (SPAC) sponsored by “Silicon Valley venture capitalist” Chamath Palihapitiya.\nToday, as I write this, it’s worth approximately $1.94 billion, 74% less than it’s $7 billion valuation.\nWhen I last wrote about Clover Health in early December,I suggested,“only the most speculative investors ought to be anywhere near this healthcare stock.” Since then, CLOV stock has lost another 9% as we approach the end of the year.\nWhile CLOV stock is trading for pennies over $4, here are three similarly-valued stocks to buy for 2022.\nForget CLOV Stock — Buy This Instead\nAccording toFinviz.com,there are64 stocks&nbsp;with a market capitalization between $1.9 billion and $2 billion. My three picks grow sales, generate profits, and possess solid balance sheets. If you’re lucky, at least one will pay a decent dividend.\nUltimately, all three are, in my opinion, safer bets than CLOV in 2022.\nSonic Automotive(NYSE:SAH) is my first pick. It has a current market cap of $2 billion. Its stock is up 25.77% year-to-date (YTD), 258 basis points less than theS&amp;P 500.\nSonic is one of the top automotive retailers in America. Its&nbsp;119 dealerships&nbsp;are located in 17 states and represent more than 25 brands. In its latest fiscal year, it sold 93,000 new vehicles and 159,000 used vehicles, generating $9.8 billion in revenue.&nbsp; It expects to grow its revenue to $25 billion by 2025.\nFrom a brand breakdown, luxury accounts for 55% of its sales with BMW, Mercedes, and Audi accounting for 71% of its luxury vehicle sales.\nIn 2021’s third-quarter, its revenues grew by 20.6% to $3.07 billion. Its net income rose 46.9% to $84.7 million and its total debt is$1.97 billion&nbsp;or 56% of its total assets.\nThe company’s Echo Park used car business should be a big contributor as it pushes to $25 billion in sales by 2025.\nThe Second Alternative to CLOV Stock\nSally Beauty Holdings(NYSE:SBH) business and the stock bounced back in 2021. That’s great news for long-time shareholders. Up 42.8% YTD, SBH’s five-year return looks a little better as a result. However, it’s down 29% on a cumulative basis over the past 60 months.\nBack in May 2017, I compared&nbsp;Sally Beauty and&nbsp;Ulta Beauty Holdings(NASDAQ:ULTA). ULTA was on a bit of a roll, while SBH was stumbling and bumbling. So, wisely, I said ULTA was the better stock to buy. Ulta is up 28.2% since — it’s also had its ups and downs — while SBH is up 3.8% over the same period.\nHowever, I thought Sally Beauty’s restructuring at the time was gaining traction. While Covid-19 didn’t help its business, its most recent results are encouraging.\nFor all of fiscal 2021, its&nbsp;sales increased10.3% to $3.87 billion with 10.2% same-store sales growth. Its operating earnings grew 44.2% in 2021 to $622.7 million, and it managed to reduce its debt by $420 million in the past year. That puts its long-term debt at $1.38 billion or 48% of its total assets.\nOn Oct. 1, board member Denise Paulonistook over as chief executive officer (CEO)of the company. She is tasked with growing sales and profits after previous CEO Chris Brinkman thoroughly modernized its beauty business during his six-year tenure.\nA Final Possibility\nMy final alternative is&nbsp;Goldman Sachs BDC(NYSE:GSBD). It was founded in 2012 to make debt and equity investments in middle-market companies — defined as earnings before interest, taxes, depreciation and amortization (EBITDA) earnings of$5 million to $200 million— and merged with Goldman Sachs Middle Market Lending Corp. (MMLC) in October 2020.\nAs a result of the merger, GSBD’s asset base more than doubled to$3.5 billion. The MMLC shareholders received 1.1336 GSBD shares for every share of MMLC.\nGSBD had $3.11 billion in investments and $401.8 million in unfunded commitments for111 portfolio companies&nbsp;across 37 industries at the end of September. Approximately 84% of its assets are first lien loans with an average yield of 8.4%.\nIt’s essential to remember that this is an investment focused on income rather than capital appreciation. The BDC’s current quarterly distribution of $0.50 yields a very high 10.4%.\nDo not buy GSBD if you’re expecting capital appreciation. However, if you’re willing to take on more risk than a guaranteed investment, it’s an excellent way to boost your income portfolio.\nNone of these three alternatives to CLOV stock are a sure thing. But, that said, I don’t believe they possess the same amount of risk as Clover Health.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health Is Not the $2 Billion Stock to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health Is Not the $2 Billion Stock to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nClover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the ...\n\n<a href=\"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166698166","content_text":"Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the special purpose acquisition company (SPAC) sponsored by “Silicon Valley venture capitalist” Chamath Palihapitiya.\nToday, as I write this, it’s worth approximately $1.94 billion, 74% less than it’s $7 billion valuation.\nWhen I last wrote about Clover Health in early December,I suggested,“only the most speculative investors ought to be anywhere near this healthcare stock.” Since then, CLOV stock has lost another 9% as we approach the end of the year.\nWhile CLOV stock is trading for pennies over $4, here are three similarly-valued stocks to buy for 2022.\nForget CLOV Stock — Buy This Instead\nAccording toFinviz.com,there are64 stocks with a market capitalization between $1.9 billion and $2 billion. My three picks grow sales, generate profits, and possess solid balance sheets. If you’re lucky, at least one will pay a decent dividend.\nUltimately, all three are, in my opinion, safer bets than CLOV in 2022.\nSonic Automotive(NYSE:SAH) is my first pick. It has a current market cap of $2 billion. Its stock is up 25.77% year-to-date (YTD), 258 basis points less than theS&P 500.\nSonic is one of the top automotive retailers in America. Its 119 dealerships are located in 17 states and represent more than 25 brands. In its latest fiscal year, it sold 93,000 new vehicles and 159,000 used vehicles, generating $9.8 billion in revenue.  It expects to grow its revenue to $25 billion by 2025.\nFrom a brand breakdown, luxury accounts for 55% of its sales with BMW, Mercedes, and Audi accounting for 71% of its luxury vehicle sales.\nIn 2021’s third-quarter, its revenues grew by 20.6% to $3.07 billion. Its net income rose 46.9% to $84.7 million and its total debt is$1.97 billion or 56% of its total assets.\nThe company’s Echo Park used car business should be a big contributor as it pushes to $25 billion in sales by 2025.\nThe Second Alternative to CLOV Stock\nSally Beauty Holdings(NYSE:SBH) business and the stock bounced back in 2021. That’s great news for long-time shareholders. Up 42.8% YTD, SBH’s five-year return looks a little better as a result. However, it’s down 29% on a cumulative basis over the past 60 months.\nBack in May 2017, I compared Sally Beauty and Ulta Beauty Holdings(NASDAQ:ULTA). ULTA was on a bit of a roll, while SBH was stumbling and bumbling. So, wisely, I said ULTA was the better stock to buy. Ulta is up 28.2% since — it’s also had its ups and downs — while SBH is up 3.8% over the same period.\nHowever, I thought Sally Beauty’s restructuring at the time was gaining traction. While Covid-19 didn’t help its business, its most recent results are encouraging.\nFor all of fiscal 2021, its sales increased10.3% to $3.87 billion with 10.2% same-store sales growth. Its operating earnings grew 44.2% in 2021 to $622.7 million, and it managed to reduce its debt by $420 million in the past year. That puts its long-term debt at $1.38 billion or 48% of its total assets.\nOn Oct. 1, board member Denise Paulonistook over as chief executive officer (CEO)of the company. She is tasked with growing sales and profits after previous CEO Chris Brinkman thoroughly modernized its beauty business during his six-year tenure.\nA Final Possibility\nMy final alternative is Goldman Sachs BDC(NYSE:GSBD). It was founded in 2012 to make debt and equity investments in middle-market companies — defined as earnings before interest, taxes, depreciation and amortization (EBITDA) earnings of$5 million to $200 million— and merged with Goldman Sachs Middle Market Lending Corp. (MMLC) in October 2020.\nAs a result of the merger, GSBD’s asset base more than doubled to$3.5 billion. The MMLC shareholders received 1.1336 GSBD shares for every share of MMLC.\nGSBD had $3.11 billion in investments and $401.8 million in unfunded commitments for111 portfolio companies across 37 industries at the end of September. Approximately 84% of its assets are first lien loans with an average yield of 8.4%.\nIt’s essential to remember that this is an investment focused on income rather than capital appreciation. The BDC’s current quarterly distribution of $0.50 yields a very high 10.4%.\nDo not buy GSBD if you’re expecting capital appreciation. However, if you’re willing to take on more risk than a guaranteed investment, it’s an excellent way to boost your income portfolio.\nNone of these three alternatives to CLOV stock are a sure thing. But, that said, I don’t believe they possess the same amount of risk as Clover Health.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1736,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":52,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698411090"}